Dementia and Alzheimer Disease

After a follow-up of nearly 4 years, nearly half of the patients (n = 10) with baseline classification of cognitive IADL impairment and mild cognitive impairment converted to dementia.

Here's some of what is coming soon to NeurologyLive® this week.

One model of AD suggests that Aβ pathophysiology triggers downstream molecular pathways, including tauopathy, which lead to cortical neurodegeneration, and cognitive decline is further attributed to the associated neurocortical Aβ plaques.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 20, 2023.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 3, 2023.

In the letter, the FDA specifically required that Eli Lilly provide data from at least 100 patients who received a minimum of 12 months of continuous treatment with donanemab.

Sacco, who also served as president of the American Heart Association/ American Stroke Association, succumbed to a brain tumor on January 17, 2023.

Sharon Cohen, MD, FRCPC, provided an investigator perspective on the use of lecanemab for patients with Alzheimer disease and what the clinician community can take away from the trials.

Here's some of what is coming soon to NeurologyLive® this week.

Susan Abushakra, MD, chief medical officer at Alzheon, provided insight on findings from a phase 2 study in which ALZ-801 showed beneficial effects on cognition, Aß 42/40, and brain atrophy.

Sharon Cohen, MD, FRCPC, offered her insight on the significance of the lecanemab approval and what it means for patients with Alzheimer disease.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 13, 2023.

The behavioral neurologist and medical director of the Toronto Memory Program provided perspective on the steps the general public can take toward reducing the risk of Alzheimer disease and initiating treatment early when needed. [WATCH TIME: 4 minutes]

Dr. Cohen shares factors that may have contributed to the high failure rate of Alzheimer’s disease clinical trials thus far.

Drs McDade and Cohen discuss ATN (amyloid, tau, neurodegeneration) classification and its use in clinical practice to manage Alzheimer’s disease.

The assistant professor of neurology at the University of Virginia spoke at the 2022 AES Conference about clinical outcomes of patients with dementia who experience seizures. [WATCH TIME: 5 minutes]

The president and chief executive officer of INmune bio provided perspective on the need to diversify the Alzheimer treatment landscape and the potential role of TNF inhibitors like XPro1595.

The director of the Montefiore Einstein Center for the Aging Brain provided insight on how the 5-Cog assessment tool is specifically tailored for people from a range of racial and ethnic background, education levels, and socioeconomic circumstances. [WATCH TIME: 4 minutes]

A population-based incident of Parkinson disease cases showed patients were more likely to develop PD dementia in 10 years with a lower level of lysosomal enzyme glucocerebrosidase activity.

The behavioral neurologist and medical director of the Toronto Memory Program provided perspective on how lecanemab’s FDA approval changes the capabilities of treating Alzheimer disease in its earliest stages. [WATCH TIME: 3 minutes]

Approved under the accelerated approval pathway, the current indication for lecanemab states the company must provide phase 4 study evidence to confirm the agent’s effect in Alzheimer disease.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Alzheimer disease and dementia.

Neurology News Network for the week ending January 7, 2022. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 6, 2023.

Marketed as Leqembi, the agent was approved through the accelerated approval pathway and was based on a major study featuring almost 900 patients with early Alzheimer disease.

Findings from a large-scale trial of adults aged 65 and older with Parkinson disease showed that treatment with pimavanserin was associated with lower risk of mortality than other atypical antipsychotics.

In the phase 3 Clarity AD trial, a 65-year-old patient treated with lecanemab died because of multiple cerebral hemorrhages after undergoing tissue plasminogen activator therapy for ischemic stroke.

Dr Cohen emphasizes the importance of engagement of primary care physicians in identification of Alzheimer’s disease symptoms and pathology.

Dr. Atri discusses his approach to diagnosis and Dr. McDade updates on the use of tau-PET for diagnosis of Alzheimer’s disease.